Targeting Protein Trafficking in Arrhythmogenic Cardiomyopathy

Information

  • Research Project
  • 10301665
  • ApplicationId
    10301665
  • Core Project Number
    K08HL155886
  • Full Project Number
    1K08HL155886-01A1
  • Serial Number
    155886
  • FOA Number
    PA-20-203
  • Sub Project Id
  • Project Start Date
    9/15/2021 - 3 years ago
  • Project End Date
    8/31/2026 - a year from now
  • Program Officer Name
    HUANG, LI-SHIN
  • Budget Start Date
    9/15/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    9/8/2021 - 3 years ago
Organizations

Targeting Protein Trafficking in Arrhythmogenic Cardiomyopathy

ABSTRACT This proposal is to support the career development of Joseph Palatinus, MD, PhD, to become an independent physician scientist with a focus on basic/translational research by targeting protein trafficking as a means to prevent and treat arrhythmias and sudden cardiac death (SCD). The PI will have as a primary mentor Professor Robin Shaw, MD PhD, who is world renowned expert in protein trafficking and cardiomyocyte biology. The comprehensive training program is composed of laboratory-based research, coursework, workshops, grantsmanship seminars, scientific conferences (local and international), and career guidance by a mentoring committee. The committee includes the mentors and leverages the combined experience and technical knowledge of 5 leading independent cardiovascular investigators at the Eccles Cardiovascular Research and Training Institute at the University of Utah as well as Dr. Jeffery Saffitz at Harvard Medical School, a world expert on Arrhythmogenic cardiomyopathy. The research proposed will apply the alternatively translated isoform of Connexin 43 (Cx43), dubbed GJA1-20k (and an established actin stabilizing protein), to the Desmoglein 2 (DSG2) mutant model of ACM. Preliminary data has demonstrated disrupted actin organization in both cellular and animal models of a DSG2 mutation which, in the heart is associated with a loss of gap junction trafficking to the intercalated disk and downstream cardiac dysfunction. It is hypothesized that GJA1-20k will lead to recovery of gap junction localization, suppression of arrhythmias and prevention of SCD in the DSG2 mutant model of ACM by directly interacting with and stabilizing cellular actin. Two specific aims are proposed: 1) Is actin dysregulation responsible for the trafficking defects observed in the DSG2 mutant model? And 2) Does GJA1- 20k rescue the cardiomyopathic and arrhythmogenic phenotype of ACM and prevent SCD? High resolution confocal microscopy, proximity ligation immunolabeling, electron microscopy, co- immunoprecipitation, echocardiography, and in vivo telemetry monitoring are some of the advanced techniques which will be used to develop a mechanistic understanding of actin dependent trafficking mediated by GJA1-20k. The results from this study are expected to develop a novel paradigm to treat and prevent arrhythmogenic SCD by targeting protein trafficking.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    K08
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
    166000
  • Indirect Cost Amount
    13280
  • Total Cost
    179280
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:179280\
  • Funding Mechanism
    OTHER RESEARCH-RELATED
  • Study Section
    MCBS
  • Study Section Name
    NHLBI Mentored Clinical and Basic Science Study Section
  • Organization Name
    UNIVERSITY OF UTAH
  • Organization Department
    INTERNAL MEDICINE/MEDICINE
  • Organization DUNS
    009095365
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    841128930
  • Organization District
    UNITED STATES